Compare Regeneron Pharmaceuticals Inc (REGN) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Tidewater Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Tidewater Inc trades at $76.97 (market cap $3.88B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 18.2× Tidewater Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| REGN | TDW | |
|---|---|---|
Market Cap | $70.79B | $3.88B |
Sector | Health | Utilities |
52-Week High | $812.27 | $91.12 |
52-Week Low | $545.46 | $47.29 |
Enterprise Value | $64.74B | $3.99B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Tidewater (TDW) trades at $75.43, down 0.51% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent earnings show mixed results, missing Q1 2026 estimates with $0.12 EPS versus $0.75 expected. The company maintains strong profitability with a 22.16% net margin and 24.03% ROE, while valuation ratios like a P/E of 12.72 suggest potential undervaluation. News highlights include the acquisition of Tidewater Logistics by FTAI Infrastructure in June 2026.
The outlook is cautiously optimistic due to solid fundamentals and analyst buy ratings, but risks include earnings volatility and sector sensitivity. Upside potential hinges on execution improvements, while downside risks stem from energy market fluctuations and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
